Gabather AB (FRA:5J2) Book Value per Share: €0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Gabather AB Book Value per Share?

Gabather AB FRA:5J2 Book Value per Share is €0.00 as of Mar. 2026. The stock has 2 warning signs investors should review.

Gabather AB's book value per share for the quarter that ended in Mar. 2026 was €0.00.

During the past 12 months, Gabather AB's average Book Value Per Share Growth Rate was 150.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -68.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Gabather AB was 26.40% per year. The lowest was -75.30% per year. And the median was -34.50% per year.

Gabather AB's current price is €0.0002. Its book value per share for the quarter that ended in Mar. 2026 was €0.00. Hence, today's PB Ratio of Gabather AB is .

During the past 12 years, the highest P/B Ratio of Gabather AB was 6.20. The lowest was 0.01. And the median was 0.71.

Warning Sign:

Gabather AB stock PB Ratio (=5.96) is close to 10-year high of 6.2.


Gabather AB  (FRA:5J2) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Gabather AB Book Value per Share Related Terms


Gabather AB Book Value per Share Historical Data

* Premium members only.

The historical data trend for Gabather AB's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gabather AB Book Value per Share Chart

Gabather AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.01 0.00 -0.00 0.00

Gabather AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.00

FRA:5J2 vs ZTS, UTHR, VTRS: Book Value per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gabather AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gabather AB PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gabather AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where Gabather AB's PB Ratio falls into.



Gabather AB Book Value per Share Calculation

Gabather AB's Book Value Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(0.06-0.00)/430.63
=0.00

Gabather AB's Book Value Per Share for the quarter that ended in Mar. 2026 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(0.26-0.00)/610.49
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of €0.00 mean?
Gabather AB (FRA:5J2) has a Book Value per Share of €0.00 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Gabather AB and its competitors.
Is Gabather AB's Book Value per Share too high?
Gabather AB's current Book Value per Share is €0.00.
How does Gabather AB's Book Value per Share compare to ZTS and UTHR?
Gabather AB's Book Value per Share of €0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Gabather AB and its competitors. Gabather AB's current Book Value per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gabather AB stock overvalued right now?
Gabather AB (FRA:5J2) has a current Book Value per Share of €0.00. The current Book Value per Share is €0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Gabather AB (FRA:5J2), the current Book Value per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gabather AB Business Description

Other Exchanges GABA:Sweden
Address Forskargatan 20J, Byggn 215 N, Sodertalje, SWE, 151 36
Gabather AB is engaged in developing novel drugs to treat several diseases originating in the central nervous system. It has four main focus areas anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including for Alzheimer's disease.